AI driven discovery Secarna leverages its proprietary OligoCreator platform to develop highly specific oligonucleotide therapeutics, presenting opportunities to offer AI powered tooling, data analytics services, or collaboration on target discovery and optimization for potential partners in immuno-oncology and genetic disease spaces.

Partnership expansion Recent and ongoing partnerships with Protalix Biotherapeutics and Scenic Biotech indicate a strong appetite for co development. Target prospective collaborators in rare diseases, genetic disorders, and renal indications where oligonucleotide approaches have clear competitive advantages.

Clinical pipeline With over 20 discovery and development programs, Secarna demonstrates a robust pipeline breadth. This suggests sales potential for CRO support, translational research services, and platform licensing to accelerate preclinical to clinical milestones for multiple therapeutic targets.

Executive leadership Key leadership transition and advisory appointments (CEO leadership, Scientific Advisory Board expansion) signal a strategic emphasis on growth and collaboration. Engage at the executive and board level to propose co development, investment, or joint venture opportunities aligned with their growth agenda.

Industry interest Active collaborations across immunology, virology, neurodegenerative, and cardiometabolic areas, plus interest from biotech manufacturing and materials partners (e.g., Celanese collaboration) indicate cross sector interest. Position adjacent services such as manufacturing process development, oligo manufacturing scale up, and technology transfer proposals to diversify potential revenue streams.